Fasting hyperglycemia: etiology, diagnosis, and treatment.
Level 5 - mechanism / opinion, no new human data
Narrative review without systematic methodology
PubMed 15321011 · doi:10.1089/1520915041705910
What was done
This narrative review examines the pathophysiology, differential diagnosis (inadequate hepatic insulinization, dawn phenomenon, and Somogyi effect), and management strategies for fasting hyperglycemia in type 1 and type 2 diabetes, emphasizing overnight glucose monitoring, dietary changes, oral agents, and bedtime basal insulin (NPH or glargine).
What was found
The abstract reports no numerical data or effect sizes. It describes fasting hyperglycemia as primarily driven by increased hepatic glucose output due to circadian hormonal dysregulation or inadequate hepatic insulinization, noting that normalization of fasting blood glucose minimizes glucotoxicity and improves daytime glycemic control.
Why it matters
Fasting hyperglycemia directly influences overall daytime glucose levels and vascular complication risks. Understanding its distinct etiologies prevents inappropriate treatment adjustments and supports targeted basal insulin or lifestyle interventions.
Limits
This is a narrative review presenting clinical overviews rather than empirical trial data or a systematic review. No quantitative estimates, sample sizes, or formal risk-of-bias assessments are reported in the abstract.
Cited by
- supports The Somogyi effect occurs when blood sugar drops very low in the early morning, triggering reactive fasting hyperglycemia.